LB Pharmaceuticals, Inc. (LBRX)
28.34
-0.05
(-0.18%)
USD |
NASDAQ |
Jun 11, 09:48
LB Pharmaceuticals SG&A Expense (Quarterly) : 7.459M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 7.459M |
| December 31, 2025 | 5.387M |
| September 30, 2025 | 2.827M |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| March 31, 2023 | 0.00 |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| NRX Pharmaceuticals, Inc. | 3.813M |
| Alto Neuroscience, Inc. | 6.844M |
| ANI Pharmaceuticals, Inc. | 73.66M |
| Corcept Therapeutics, Inc. | 145.36M |
| Assertio Holdings, Inc. | 11.14M |